<DOC>
	<DOCNO>NCT02780167</DOCNO>
	<brief_summary>Study B7451006 Phase 2b POC study plan assess four PF 04965842 daily ( QD ) dose ( 10 , 30 , 100 , 200 mg ) relative placebo 12 week characterize efficacy safety PF 04965842 subject moderate severe AD . The objective study demonstrate efficacy PF 04965842 show improvement disease severity patient moderate severe AD measure Investigator 's Global Assessment ( IGA ) Eczema Area Severity Index ( EASI ) score , safety support clinical development PF 04965842 .</brief_summary>
	<brief_title>Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female subject 18 75 year age , inclusive , time informed consent . Must follow atopic dermatitis criterion : 1 . Have clinical diagnosis chronic atopic dermatitis ( also know atopic eczema ) least 1 year prior Day 1 confirm atopic dermatitis ( Hanifin Rajka criterion AD refer Appendix 2 ) Screening visit . 2 . Have inadequate response treatment topical medication give least 4 week , topical treatment otherwise medically inadvisable ( eg , important side effect safety risk ) within 12 month first dose study drug . 3 . Moderate severe AD ( affect BSA &gt; =10 % , IGA &gt; =3 , EASI &gt; =12 screen baseline visit ) . History human immunodeficiency virus ( HIV ) positive HIV serology screening , Infected hepatitis B hepatitis C virus . Have evidence active latent inadequately treated infection Mycobacterium tuberculosis ( TB ) Have receive following treatment regiment specify timeframes outline : Within 6 month first dose study drug : Any cell deplete agent Within 12 week first dose study drug : Any study JAK inhibitor ; Other biologics Within 8 week first dose study drug : Participation study involve investigational drug ( ) Within 6 week first dose study drug : Have vaccinate live attenuate live vaccine . Within 4 week first dose study drug : Use oral immune suppressant ; Phototherapy ( NB UVB ) broad band phototherapy ; Regular use ( 2 visit per week ) tan booth/parlor . Within 1 week first dose study drug : Topical treatment could affect atopic dermatitis ; Herbal medication unknown property know beneficial effect AD .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>randomize</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo</keyword>
	<keyword>atopic dermatitis</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>JAK</keyword>
	<keyword>janus kinase</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
</DOC>